Related references
Note: Only part of the references are listed.Real-World Efficacy of 5-Azacytidine as Salvage Chemotherapy for Angioimmunoblastic T-cell Lymphoma
Sang Eun Yoon et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)
Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study
Jehan Dupuis et al.
BLOOD (2022)
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study
Lorenzo Falchi et al.
BLOOD (2021)
Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways
Luigi Scotto et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials
Helen Ma et al.
HEMATOLOGICAL ONCOLOGY (2020)
The peripheral T-cell lymphomas: an unusual path to cure
Helen Ma et al.
Lancet Haematology (2020)
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study
Owen A. O'Connor et al.
BLOOD (2019)
The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma
Enrica Marchi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors
Vivien Mak et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters
Francois Lemonnier et al.
BLOOD (2012)
TET2 and DNMT3A Mutations in Human T-Cell Lymphoma
Lucile Couronne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL
Matko Kalac et al.
BLOOD (2011)
Share Paper
